Skip to content

Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects

Effects of Dietary Fructose on Glucose and Lipid Metabolism in Healthy Human Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01021969
Enrollment
36
Registered
2009-12-01
Start date
2007-06-30
Completion date
2011-07-31
Last updated
2011-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The increasing intake of fructose has been associated with an increase in obesity among US children and adolescents, but its dose dependent effects on insulin sensitivity and lipid metabolism has not been studied in detail. Methods: 36 healthy male adult human subjects will be included in this study. They will be randomly allocated into a low, moderate or high fructose, a moderate or high glucose and a sucrose diet for 3 weeks. In randomized order and with 4 week wash out intervals each subject will receive all six different diets. Three day food records will be used to measure total fructose and glucose intake. During the low fructose diet subjects will be instructed to avoid nutrients containing fructose aiming at consumption of less than 1g fructose/d. During the moderate fructose diet subjects will receive 3x13.3g of fructose or glucose, respectively. High fructose diet subjects will receive either 3x26.7g/d of fructose, 3x 26.7g/d of glucose or 3x 26.7g/d of sucrose in the form of three daily soft drinks taken together with the three main meals. 75 g oral glucose tolerance testing will be performed and composite insulin sensitivity index will be calculated The presence of phosphorylated fructose metabolites in plasma will be measured by targeted LC-MS/MS. In addition, metabolite biomarkers in plasma will be screened by untargeted metabolite profiling using both LC-MS and GC-MS. In a subgroup of 10 subjects an euglycemic hyperinsulinemic clamp will be performed using \[6,6- 2H2\]glucose. Thus, the lipogenic potential of fructose in humans will be compared with isocaloric amounts of glucose. Particularly, the question whether lipogenic effects are continuously dose dependent or whether there is a lipogenic shunting and if yes, at what level of ingested fructose will be addressed.

Interventions

OTHERFructose

Subjects consume different amounts of fructose, glucose and sucrose in a crossover design

Sponsors

Swiss National Science Foundation
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Healthy male volunteers aged 20-50y with a BMI between 19 and 25 kg/m2

Exclusion criteria

* Acute infection, malignant disease, renal (abnormal creatinine), hepatic (more than two-fold increased transaminases), pulmonary, neurological (epilepsy) or major psychiatric diseases, manifested atherosclerosis * Fasting plasma glucose \> 5.6 mmol/l * Known alcohol or drug abuse * HIV-antibody positive * Subjects likely to fail to comply with the study protocol * Smoking (\>1 cigarette/month) * Subjects who do not give informed consent Additional

Design outcomes

Primary

MeasureTime frame
LDL sizebaseline and after each of 6 interventions

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026